Patents Assigned to SEAGEN INC.
  • PROCESS FOR MAKING AURISTATIN CONTAINING COMPOUNDS
    Publication number: 20260200970
    Abstract: Processes for making auristatin compounds such as maleimidocaproyl monomethyl Auristatin F (1), Formula (1) are described herein.
    Type: Application
    Filed: December 8, 2023
    Publication date: July 16, 2026
    Applicant: Seagen Inc.
    Inventors: Ian ANDREWS, John L. WOODARD, Anthony Joseph NOCKET, John Anthony KOWALSKI, Greg Alan ERICKSON, Danny Emilio MANHENO, Michel JOURNET, Qiaogong SU, Christopher REIHER, Kenneth Lamar ARRINGTON
  • Methods of Treating Cancer Using Anti-HER2 Antibody-Drug Conjugates
    Publication number: 20260158154
    Abstract: Provided herein are methods for treating or preventing progression of cancer in an individual, comprising administering to the individual an effective amount of an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that comprises an anti-HER2 antibody and a cytotoxic molecule.
    Type: Application
    Filed: February 12, 2026
    Publication date: June 11, 2026
    Applicant: Seagen Inc.
    Inventors: Nicholas Wei Wen Choong, Xuemei Li
  • Detection and treatment of CD30+ cancers
    Patent number: 12590968
    Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: March 31, 2026
    Assignee: SEAGEN INC.
    Inventors: Tina Albertson, Maria L. Smith
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20260034234
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 14, 2025
    Publication date: February 5, 2026
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20260000604
    Abstract: A pharmaceutical composition comprising an antibody drug conjugate comprising an antibody or antigen binding fragment thereof that binds to 191P4D12 conjugated to one or more units of monomethyl auri statin E (MMAE) and a pharmaceutically acceptable excipient comprising L-histidine, polysorbate-20 (TWEEN-20), and at least one of trehalose dihydrate and sucrose.
    Type: Application
    Filed: February 19, 2025
    Publication date: January 1, 2026
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Orla MCGARVEY, Gayathri RATNASWAMY, Yingqing SUN, Marie Rose VAN SCHRAVENDIJK
  • Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
    Patent number: 12496353
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: December 16, 2025
    Assignee: SEAGEN INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • CD25 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF
    Publication number: 20250295801
    Abstract: Antigen binding proteins such as antibodies and fragments thereof that bind CD25 are provided. Nucleic acids encoding such antigen binding proteins and vectors and cells useful in preparing such antigen binding proteins are also provided. Also provided are antibody-drug conjugates comprising such antigen binding proteins. The antigen binding proteins and antibody-drug conjugates are useful in a variety of methods, including the treatment of CD25 expressing and non-CD25 expressing tumors.
    Type: Application
    Filed: March 18, 2025
    Publication date: September 25, 2025
    Applicant: Seagen Inc.
    Inventors: Matthew Levengood, Shyra Gardai, Sherif Abdelhamed, Paromita Raha
  • Anti-PD-L1 antibodies and antibody-drug conjugates
    Patent number: 12421312
    Abstract: Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 23, 2025
    Assignee: Seagen Inc.
    Inventors: Byron Hua Kwan, Heather Van Epps, Andrew Waight, Scott Jeffrey, Ryan Lyski
  • ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20250276076
    Abstract: Antigen binding proteins such as antibodies and fragments thereof that bind ALPP and/or ALPPL2 are provided. Nucleic acids encoding such antigen binding proteins and vectors and cells useful in preparing such antigen binding proteins are also provided. The antigen binding proteins are useful in a variety of methods, including the treatment of ovarian cancer.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 4, 2025
    Applicant: SEAGEN INC.
    Inventors: Hector De Jesus Rincon Arano, Sarah Ann Riordan Anderson, Erin Margaret Scherer, Lori Westendorf, Noah Bindman, Nicole Okeley, Peter Senter, Divya Awasthi
  • CAMPTOTHECIN CONJUGATES
    Publication number: 20250248994
    Abstract: Antibody conjugates with camptothecin compounds are described, with methods of use and preparations.
    Type: Application
    Filed: March 24, 2025
    Publication date: August 7, 2025
    Applicant: Seagen Inc.
    Inventors: Scott JEFFREY, Ryan LYSKI, Uland LAU
  • ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20250242041
    Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: March 3, 2025
    Publication date: July 31, 2025
    Applicant: Seagen Inc.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CD30 ANTIBODY DRUG CONJUGATE
    Publication number: 20250179182
    Abstract: The invention provides an anti-PD-1 antibody and an antibody-drug conjugate that binds to CD30 and their use in methods of treating solid tumors. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to CD30 for use in treating solid tumors.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 5, 2025
    Applicant: SEAGEN INC.
    Inventors: Ryan Heiser, Scott Knowles, Markus Puhlmann
  • METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20250135020
    Abstract: Provided herein are methods for the intravesical treatment of bladder cancer and methods for treating non-muscle invasive bladder cancer with antibody drug conjugates (ADC) that bind to 191P4D12 protein (Nectin-4).
    Type: Application
    Filed: August 12, 2022
    Publication date: May 1, 2025
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Christopher CAROSINO, Sujata NARAYANAN, Amit GARG
  • Anti-?V?6 antibodies and antibody-drug conjugates
    Patent number: 12268751
    Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Grant
    Filed: October 18, 2023
    Date of Patent: April 8, 2025
    Assignee: Seagen Inc.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
    Patent number: 12257340
    Abstract: A pharmaceutical composition comprising an antibody drug conjugate comprising an antibody or antigen binding fragment thereof that binds to 191P4D12 conjugated to one or more units of monomethyl auristatin E (MMAE) and a pharmaceutically acceptable excipient comprising L-histidine, polysorbate-20 (TWEEN-20), and at least one of trehalose dihydrate and sucrose.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: March 25, 2025
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Orla McGarvey, Gayathri Ratnaswamy, Yingqing Sun, Marie Rose Van Schravendijk
  • Hydrophilic antibody-drug conjugates
    Patent number: 12257281
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: March 25, 2025
    Assignee: Seagen Inc.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • METHODS FOR TREATING MUSCLE INVASIVE UROTHELIAL CANCER OR MUSCLE INVASIVE BLADDER CANCER WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20250064956
    Abstract: Provided herein are methods for treating urothelial or bladder cancers with antibody drug conjugates (ADC) that bind to 191P4D12 protein (Nectin-4).
    Type: Application
    Filed: January 4, 2023
    Publication date: February 27, 2025
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Anne-Sophie CARRET, Oyewale O. ABIDOYE
  • Camptothecin conjugates
    Patent number: 12194321
    Abstract: Antibody conjugates with camptothecin compounds are described, with methods of use and preparations.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: January 14, 2025
    Assignee: Seagen Inc.
    Inventors: Scott Jeffrey, Ryan Lyski, Uland Lau
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20240415917
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula I.: or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: August 9, 2024
    Publication date: December 19, 2024
    Applicant: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Improved Antibody Masking Domains
    Publication number: 20240376200
    Abstract: Improved masking domains and masked antibodies comprising improved masking domains are provided. In some embodiments, masked antibodies comprising the improved masking domains demonstrate reduced aggregation. In various embodiments, masked antibodies comprising the improved masking domains may be used in therapeutic treatment.
    Type: Application
    Filed: September 23, 2022
    Publication date: November 14, 2024
    Applicant: Seagen Inc.
    Inventor: Matthew Levengood